VIDEO: Innocan $INNO.ca Completes Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) #CBD Premium Facial Serum on Skin Hydration $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) has completed a cosmetic clinical study examining the impact of its SHIR ™ Premium CBD Facial Serum containing 300 mg of cannabidiol (“CBD“) on skin hydration.

• Study was conducted by an independent research laboratory: INOVAPOTEK, Pharmaceutical Research and Development in Portugal”.
• The study aimed to assess the hydrating efficacy of the Serum in vivo, by measuring the skin capacitance for a period of 2, 4, 8 and 24 hours after the CBD Serum application on the skin.
• The results demonstrated that there were significant hydration increases for each period.
• The Serum was well tolerated with no uncomfortable symptoms or feelings reported by the subjects of the study.

In addition, the research laboratory completed a clinical controlled study for the evaluation of the acute cutaneous irritation potential of cosmetic products. All of the SHIR™ Derma Cosmetic products tested to date have demonstrated to be non-irritating under the test conditions.

Read Full Release

Last modified: July 13, 2026